Payment overview · 2025
General Payments
$275.79
7 reported records · 6 companies
Healthcare provider profile · identity verified
Katherine Marcel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BATON ROUGE, LA · NPI 1104288570
Verified facts
What the public records show
CMS Open Payments records show Katherine Marcel, MD received $275.79 in general payments during 2025 across 7 reported records.
Medtronic, Inc. accounted for 54.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$150.92 | 54.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.82 | 11.9% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $27.78 | 10.1% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.87 | 9.4% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.32 | 7.4% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $18.08 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $275.79 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $150.92 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $32.82 | 2 | 2025 |
Source payment records
|
|||||
| ALVESCO Normalized: alvesco |
Drug | Azurity Pharmaceuticals, Inc. | $25.87 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| VTAMA Normalized: vtama |
Drug | Organon LLC | $18.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 332 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 293 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 197 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 181 | 67 |
| Mounjaro | Tirzepatide | 150 | 28 |
| Losartan Potassium | Losartan Potassium | 149 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 42 |
| Gabapentin | Gabapentin | 121 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 115 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 34 |
| Montelukast Sodium | Montelukast Sodium | 101 | 31 |
| Bupropion Xl | Bupropion Hcl | 95 | 31 |
| Omeprazole | Omeprazole | 94 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 18 |
| Lisinopril | Lisinopril | 91 | 32 |
| Alprazolam | Alprazolam | 86 | 27 |
| Trazodone Hcl | Trazodone Hcl | 85 | 27 |
| Sertraline Hcl | Sertraline Hcl | 84 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 30 |
| Ozempic | Semaglutide | 81 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 25 |
| Buspirone Hcl | Buspirone Hcl | 67 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 19 |
| Mirtazapine | Mirtazapine | 65 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 16 |
| Clonazepam | Clonazepam | 60 | 16 |
| Metformin Hcl | Metformin Hcl | 60 | 26 |
| Ezetimibe | Ezetimibe | 59 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 15 |
| Meloxicam | Meloxicam | 54 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 17 |
| Baclofen | Baclofen | 48 | 16 |
| Nifedipine Er | Nifedipine | 48 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 15 |
| Metformin Hcl Er | Metformin Hcl | 47 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 18 |
| Carvedilol | Carvedilol | 42 | 11 |
| Glimepiride | Glimepiride | 39 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 38 | suppressed |
| Simvastatin | Simvastatin | 36 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Potassium Chloride | Potassium Chloride | 35 | 13 |
| Synthroid | Levothyroxine Sodium | 35 | 11 |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Furosemide | Furosemide | 31 | 12 |
| Jardiance | Empagliflozin | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 16 |
| Mupirocin | Mupirocin | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Nystatin | Nystatin | 26 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Estradiol | Estradiol | 25 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 25 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Cefdinir | Cefdinir | 22 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 20 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Azithromycin | Azithromycin | 14 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $275.79 · 7 records | Medtronic, Inc. | ALVESCO, FANAPT, INTERSTIM, TEZSPIRE, VTAMA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error